Kura Oncology Inc
Research Kura Oncology Inc (KURA) on Bullrun: market cap USD 924.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKURA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 924.68M
- Financial periodQ2 2026
- RevenueUSD 20.87M
- Net income-USD 68.33M
- Free cash flow-USD 63.21M
- Gross margin98.8%
Valuation Snapshot
latest market cap is USD 924.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 67.48M | -USD 278.67M | -USD 70.70M | 99.9% | -3.18 | USD 149.10M | USD 9.71M | USD 174.14M |
| FY2024 | USD 53.88M | -USD 173.98M | USD 133.85M | 100.0% | -2.02 | USD 224.46M | USD 9.52M | USD 413.64M |
| FY2023 | USD 0 | -USD 152.63M | -USD 124.99M | n/a | -2.08 | USD 37.32M | USD 9.33M | USD 397.27M |
| FY2022 | USD 0 | -USD 135.84M | -USD 110.69M | n/a | -2.03 | USD 51.80M | USD 9.16M | USD 420.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 924.68M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 912.81M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 681.37M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.07B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 847.15M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 932.01M | n/a | n/a | n/a |
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kura Oncology Inc's market cap?
Kura Oncology Inc's market capitalization is USD 924.68M.
What does Kura Oncology Inc do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in.